Andrew Davies, MRCP, PhD of University Hospital of Southampton, Southampton, UK talks about upcoming trials in diffuse large B-cell lymphoma (DLBCL). First, he discusses an upcoming trial of R-CHOP in combination with a second generation BTK inhibitor (acalabrutinib). Dr Davies explains that this building on the platform developed for the REMoDL-B study where they determined cell of origin in real-time in order to stratify patients (NCT01324596). Further, there is a relapsed DLBCL trial of obinutuzumab combined with a checkpoint inhibitor (PD-L1 inhibitor) bulked on a chemotherapy backbone of gemcitabine and oxaliplatin. The aim is to understand biomarkers for response, i.e. there is a lot of correlative translational work going on.
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
